David Schulman

Partner

Washington, D.C.

David Schulman is a trusted advisor to life sciences companies on complex global transactions.

He provides strategic guidance on transactions involving mergers, acquisitions, collaborations, strategic alliances, licenses, capital markets, royalty and revenue-sharing and other financings for pharmaceutical and biotechnology companies and financial sponsors.

David is highly ranked for his life sciences work by Chambers USA and Chambers Global, with clients recognizing him as “one of the best business and corporate lawyers in the life sciences sector” with “a deep knowledge of the industry, which he successfully combines with great legal skills.” He has also been recognized by The Legal 500 and is listed as a “Life Sciences Star” in LMG Life Sciences.

Prior to joining Orrick, David was a partner with Dechert LLP, based in its Washington, D.C., and London offices and was a co-head of their Life Sciences practice. He is currently a member of the Board of Overseers of the School of Arts and Sciences of the University of Pennsylvania.

  • Representative client representations include advising:

    • BioAtla, Inc. (NASDAQ: BCAB) in its $189 million initial public offering (with J.P. Morgan, Jefferies and Credit Suisse acting as joint book-running managers) and on its 2019 global collaboration with BeiGene
    • LEXEO Therapeutics on its $85 million Series A financing
    • Ferring Pharmaceuticals on numerous M&A and collaboration transactions, including the 2020 co-promotion collaboration with UCB for CIMZIA and 2019 joint investment with Blackstone Life Sciences of over $570 million in FerGene
    • Valneva SE (EPA: VLA) on its Lyme Disease collaboration with Pfizer Inc. where Valneva is eligible to receive a total of $308 million cash payments consisting of a $130 million upfront payment, $35 million in development milestones and $143 million in early commercialization milestones, together with tiered royalties starting at 19% and specified development cost-sharing, and on numerous additional licenses and acquisitions
    • Celgene Corporation on numerous collaboration, licensing and M&A transactions, including numerous collaboration and M&A deals involving upfront milestones and other payments between $50 million and $1 billion with Evotec AG, Juno Therapeutics, Agios Pharmaceuticals, Vividion Therapeutics, Anokion SA, Nogra Pharma, AstraZeneca, Jounce Therapeutics, Nurix, Quanticel Pharmaceuticals, Sutro BioPharma, Forma Therapeutics, OncoMed, bluebird bio, Epizyme, Avila Therapeutics and MorphoSys AG.
    • Adocia SA on numerous licenses and collaborations, including with Eli Lilly
    • Newron Pharmaceuticals SpA on numerous licenses and collaborations including with Meiji Pharmaceuticals and Zambon SpA
    • Pfizer on numerous M&A and collaboration transactions, including co-promotions involving Lipitor, Celebrex, Spiriva and Rebif blockbuster pharmaceutical drugs